The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer

Nat Commun. 2023 Apr 8;14(1):1986. doi: 10.1038/s41467-023-37616-4.

Abstract

Heterogeneous antigen expression is a key barrier influencing the activity of chimeric antigen receptor (CAR) T cells in solid tumors. Here, we develop CAR T cells targeting glypican-1 (GPC1), an oncofetal antigen expressed in pancreatic cancer. We report the generation of dromedary camel VHH nanobody (D4)-based CAR T cells targeting GPC1 and the optimization of the hinge (H) and transmembrane domain (TM) to improve activity. We find that a structurally rigid IgG4H and CD28TM domain brings the two D4 fragments in proximity, driving CAR dimerization and leading to enhanced T-cell signaling and tumor regression in pancreatic cancer models with low antigen density in female mice. Furthermore, single-cell-based proteomic and transcriptomic analysis of D4-IgG4H-CD28TM CAR T cells reveals specific genes (e.g., HMGB1) associated with high T-cell polyfunctionality. This study demonstrates the potential of VHH-based CAR T for pancreatic cancer therapy and provides an engineering strategy for developing potent CAR T cells targeting membrane-distal epitopes.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • CD28 Antigens* / metabolism
  • Cell Line, Tumor
  • Epitopes / metabolism
  • Female
  • Glypicans / genetics
  • Glypicans / metabolism
  • Immunotherapy, Adoptive
  • Mice
  • Pancreatic Neoplasms* / metabolism
  • Pancreatic Neoplasms* / therapy
  • Proteomics
  • Receptors, Antigen, T-Cell / metabolism
  • T-Lymphocytes
  • Xenograft Model Antitumor Assays

Substances

  • CD28 Antigens
  • Glypicans
  • Epitopes
  • Receptors, Antigen, T-Cell